Personalis EBITDA 2018-2024 | PSNL

Personalis ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Personalis Annual EBITDA
(Millions of US $)
2023 $-101
2022 $-107
2021 $-57
2020 $-36
2019 $-18
2018 $-11
2017 $-21
Personalis Quarterly EBITDA
(Millions of US $)
2024-09-30 $-12
2024-06-30 $-15
2024-03-31 $-17
2023-12-31 $-22
2023-09-30 $-29
2023-06-30 $-23
2023-03-31 $-27
2022-12-31 $-29
2022-09-30 $-25
2022-06-30 $-26
2022-03-31 $-26
2021-12-31 $-18
2021-09-30 $-16
2021-06-30 $-13
2021-03-31 $-10
2020-12-31 $-12
2020-09-30 $-8
2020-06-30 $-8
2020-03-31 $-8
2019-12-31 $-6
2019-09-30 $-5
2019-06-30 $-3
2019-03-31 $-4
2018-12-31
2018-09-30 $-1
2018-06-30 $-4
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.245B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00